Dual-Cassette AAV Vector for DMD Gene Replacement and NF-κB Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for Duchenne muscular dystrophy (DMD) are complex and inefficient due to the need for multiple viral vectors and the challenge of chronic inflammation caused by up-regulated NF-κB signaling, which affects dystrophin gene replacement and muscle-specific expression.
Innovation Solution
A dual-cassette adeno-associated viral (AAV) vector system that simultaneously delivers a mini-dystrophin gene and NF-κB/p65-shRNA, using muscle-specific promoters and enhancers to achieve targeted expression in both skeletal and cardiac muscles, reducing inflammation and enhancing dystrophin expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If two separate AAV vectors are used to deliver mini-dystrophin and NF-κB/p65-shRNA, then both therapeutic functions are achieved, but the treatment complexity increases significantly for clinical application
Solution Approach 1:
The patent combines two separate AAV vectors into a single dual-cassette AAV vector that simultaneously delivers both mini-dystrophin and NF-κB/p65-shRNA therapeutic genes. This merging approach maintains the dual therapeutic functions while significantly simplifying the administration protocol from two separate injections to one single injection, making it clinically practical.
Solution Approach 2:
The single AAV vector is designed with multi-functionality by incorporating two independent expression cassettes: one for mini-dystrophin expression in muscle tissue and another for NF-κB/p65-shRNA expression to reduce inflammation. This universal vector platform can deliver multiple therapeutic payloads simultaneously, eliminating the need for separate vector administrations.
2Adaptability or versatility
If universal promoters like CMV are used for gene expression, then broad tissue expression is achieved, but toxicity and immune response increase
Solution Approach 1:
The patent employs muscle-specific promoters (such as MCK promoter) instead of universal promoters like CMV. These promoters are designed to drive gene expression specifically in skeletal and cardiac muscle tissues while leaving other tissues unaffected. This local quality approach ensures therapeutic genes are expressed only where needed, reducing off-target toxicity and immune responses.
3Object-generated harmful factors
If NF-κB signaling is up-regulated in DMD, then inflammatory response increases, but mini-dystrophin expression efficiency decreases
Solution Approach 1:
The patent applies preliminary anti-action by incorporating NF-κB/p65-shRNA into the dual-cassette AAV vector to preemptively suppress NF-κB signaling before it can inhibit mini-dystrophin expression. The shRNA component continuously produces small interfering RNA that targets and degrades NF-κB/p65 mRNA, preventing the transcription factor from activating inflammatory genes and repressing dystrophin expression, thereby maintaining high mini-dystrophin expression efficiency.
Data Source
AI summary
In one embodiment, the invention provides a dual-cassette gene vehicle comprising cassettes for expression of both a mini-dystrophin gene and NF-κB/p65-shRNA gene in cardiac muscle tissue and skeletal muscle tissue, which is an adeno-associated viral (AAV) vector, wherein the mini-dystrophin gene is operably linked to a construct comprising a muscle-specific first promoter and a modified Mcken (MCK) enhancer and wherein the NF-κB/p65-shRNA gene is under the control of a second promoter. Also are provided pharmaceutical compositions comprising such gene vehicles and a method for ameliorating Duchenne muscular dystrophy (DMD) employing such gene delivery vehicles and pharmaceutical compositions.